Briacell Therapeutics - 30BCTXZPreferred / convertible
13F holders, Q4 2025 (December 31)4holders +1
0new positions
0sold out
$0.29avg. 13F price*
At the end of Q4 2025, 4 institutions reported holding Briacell Therapeutics - 30 (BCTXZ) in their 13F filings, up 1 from Q3 2025. 0 opened new positions and 0 sold out. The largest holders were Empery Asset Management, LP ($193K), Heights Capital Management, Inc. ($163K) and Sabby Management, LLC ($77K).
- Company
- Briacell Therapeutics - 30
- CUSIP
- 107930117
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q3 2025 → Q4 2025: 108,585 shares sold, net −108,585 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Empery Asset Management, LP | — | — | 666,600 | $193K |
| Heights Capital Management, Inc. | — | No change | 544,698 | $163K |
| Sabby Management, LLC | — | Reduce -29.0% | 265,964 | $77K |
| UBS Group AG | — | Reduce -92.4% | 5 | $1 |
"% of holder's portfolio" is BCTXZ's weight in each manager's 13F, not the share of Briacell Therapeutics - 30 the manager owns.